Suppliers and packagers for generic pharmaceutical drug: CASIMERSEN

CASIMERSEN

Listed suppliers include manufacturers, repackagers, relabelers, and private labeling entitities.

Applicant	Tradename	Generic Name	Dosage	NDA	NDA/ANDA	Supplier	Package Code	Package	Marketing Start
Sarepta Theraps Inc	AMONDYS 45	casimersen	SOLUTION;INTRAVENOUS	213026	NDA	Sarepta Therapeutics, Inc.	60923-227-02	1 VIAL, SINGLE-USE in 1 CARTON (60923-227-02) / 2 mL in 1 VIAL, SINGLE-USE	2021-02-25

Casimersen Drug Suppliers Analysis

Last updated: February 19, 2026

This report analyzes key suppliers and manufacturing capabilities relevant to Casimersen, an antisense oligonucleotide (ASO) therapy for treating Duchenne muscular dystrophy (DMD). The analysis focuses on companies involved in the synthesis, manufacturing, and supply chain of ASO drugs, identifying potential partners and assessing market readiness.

Who are the Primary Suppliers for Casimersen and its Components?

Casimersen (brand name: KAHUNA) is an ASO drug developed by Sarepta Therapeutics. As an ASO, its active pharmaceutical ingredient (API) is a synthetic strand of nucleic acid. The manufacturing of ASO drugs involves complex multi-step synthesis, purification, and formulation. Key suppliers are therefore involved in oligonucleotide synthesis and potentially GMP manufacturing of the drug product.

Key Supplier Categories:

• Oligonucleotide Synthesis Manufacturers: Companies specializing in the chemical synthesis of DNA or RNA sequences at scale, meeting GMP (Good Manufacturing Practice) standards. These are critical for producing the API.
• Contract Development and Manufacturing Organizations (CDMOs): Organizations that provide comprehensive services from drug development through commercial manufacturing, including API synthesis, formulation, fill-finish, and packaging.
• Raw Material and Reagent Suppliers: Providers of the chemical building blocks, phosphoramidites, and other reagents essential for oligonucleotide synthesis.

Identifying specific, publicly disclosed suppliers for Casimersen's API or finished drug product is challenging due to proprietary contractual agreements between pharmaceutical companies and their manufacturing partners. However, based on industry knowledge and Sarepta's known manufacturing strategies for its ASO portfolio, certain companies are prominent in this specialized field.

Leading oligonucleotide synthesis and ASO manufacturing players include:

• Agilent Technologies: A major provider of oligonucleotide synthesis instrumentation and services, including GMP manufacturing for APIs. Agilent has a significant footprint in the oligonucleotide market and has previously partnered with ASO developers.
• LGC Biosearch Technologies: Offers a broad range of products and services for genomics, including custom oligonucleotide synthesis and GMP manufacturing capabilities.
• Nitto Avecia: A dedicated CDMO specializing in the large-scale GMP manufacturing of oligonucleotides. Nitto Avecia is a known significant player in the ASO manufacturing space and has been identified as a key partner for various ASO therapies.
• Bachem: A chemical manufacturing company with expertise in peptide and oligonucleotide synthesis. Bachem has expanded its capabilities in producing nucleic acid-based APIs, including for ASO drugs, at GMP scale.
• WuXi AppTec: A global pharmaceutical and medical device outsourcing company providing a broad range of R&D and manufacturing services. WuXi AppTec has invested significantly in oligonucleotide manufacturing capabilities to support the growing ASO market.

Sarepta Therapeutics has historically relied on a combination of internal manufacturing capabilities and external CDMO partnerships for its ASO pipeline. For KAHUNA (Casimersen), it is likely that a specialized oligonucleotide synthesis CDMO is involved in producing the API.

What are the Manufacturing Challenges for Oligonucleotide Therapeutics like Casimersen?

The manufacturing of oligonucleotide-based therapies, such as Casimersen, presents unique and significant challenges compared to traditional small-molecule drugs or even protein-based biologics. These challenges directly impact supply chain reliability, cost of goods, and scalability.

Key Manufacturing Challenges:

• Chemical Synthesis Complexity: Oligonucleotide synthesis is a highly complex multi-step chemical process. It involves sequential addition of nucleotide phosphoramidites to a growing chain. Each coupling step must be highly efficient (typically >99%) to achieve acceptable yields of full-length product. Impurities, such as truncated sequences or modified nucleotides, can significantly impact efficacy and safety.
• Scale-Up Difficulties: Transitioning from laboratory-scale synthesis to commercial-scale production (kilograms to metric tons) is technically demanding. Maintaining reaction efficiency, purity, and consistency across larger batch sizes requires specialized equipment and process optimization. Solid-phase synthesis, commonly used, becomes increasingly challenging at larger scales.
• Purity and Impurity Profiling: Achieving and maintaining high purity levels is paramount. Impurities can include deleted sequences, capped sequences, isomers, and residual reagents. Rigorous analytical methods are required for detection and quantification of these impurities, necessitating sophisticated quality control (QC) infrastructure. Regulatory agencies require extensive characterization and control of impurities.
• Cost of Raw Materials: The specialized phosphoramidite building blocks and reagents required for oligonucleotide synthesis are expensive. The cost of these raw materials contributes significantly to the overall cost of goods (COGS). Efficient synthesis pathways and strategic sourcing are crucial for cost management.
• Process Validation and Regulatory Scrutiny: Manufacturing processes for ASOs are subject to stringent regulatory oversight. Extensive validation studies are required to demonstrate that the manufacturing process consistently produces a product of the required quality. This includes process validation, analytical method validation, and stability studies.
• Handling and Stability: Oligonucleotides, particularly in their API form, can be sensitive to degradation. Proper handling, storage conditions (e.g., temperature control, protection from nucleases), and formulation are critical to maintain stability throughout the supply chain, from manufacturing to the patient.
• Waste Management: The chemical synthesis of oligonucleotides generates significant chemical waste. Environmentally responsible and compliant waste disposal adds to operational costs and complexity.
• Specialized Equipment: Dedicated, high-capacity synthesis and purification equipment are required. These systems are specialized and can represent substantial capital investment for manufacturers.

Sarepta Therapeutics has made substantial investments in its own manufacturing facilities and has cultivated strong relationships with CDMO partners to address these challenges. The company’s experience with eteplirsen (EXONDYS 51) and golodirsen (VYONDYS 53) provides a foundation for manufacturing Casimersen.

What is the Regulatory Landscape for ASO Drug Manufacturing?

The regulatory landscape for oligonucleotide-based therapeutics like Casimersen is robust and evolving, driven by the unique nature of these complex molecules and their therapeutic applications. Regulatory agencies, including the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA), apply rigorous standards to ensure the safety, efficacy, and quality of these drugs.

Key Regulatory Considerations:

• Good Manufacturing Practices (GMP): All manufacturing processes, from API synthesis to final drug product formulation and packaging, must adhere to current Good Manufacturing Practices (cGMP). This includes detailed documentation, process controls, quality assurance systems, and facility compliance.
• CMC (Chemistry, Manufacturing, and Controls) Data: Comprehensive CMC data is a critical component of regulatory submissions. This includes detailed information on:
  • API Characterization: Structural elucidation, identity, purity, impurity profile, and characterization of related substances. Advanced analytical techniques like mass spectrometry (MS), high-performance liquid chromatography (HPLC), and nuclear magnetic resonance (NMR) are essential.
  • Manufacturing Process: Detailed description of the synthesis, purification, and isolation of the API. For drug product, this includes formulation, fill-finish operations, and any sterilization steps.
  • Specifications and Test Methods: Establishment of strict specifications for the API and drug product, along with validated analytical methods to test against these specifications.
  • Stability Studies: Long-term and accelerated stability studies to define storage conditions and shelf-life.
• Impurity Control: Given the potential for process-related impurities (e.g., deleted sequences, incompletely modified nucleotides, residual reagents), regulatory agencies place a strong emphasis on the identification, qualification, and control of these impurities. Manufacturers must demonstrate a thorough understanding of potential impurities and establish acceptable limits.
• Process Validation: Regulatory bodies require robust process validation to demonstrate that the manufacturing process consistently produces a product meeting predetermined specifications and quality attributes. This involves prospective, concurrent, or retrospective validation studies.
• Supply Chain Security and Traceability: Manufacturers must ensure the integrity and traceability of their supply chain, from raw materials to finished product. This includes managing third-party suppliers and ensuring their compliance with relevant regulations.
• Post-Approval Changes: Any changes to the manufacturing process, facility, or analytical methods post-approval require regulatory review and approval, depending on the significance of the change.
• Orphan Drug Designations and Expedited Pathways: Therapies for rare diseases like Duchenne muscular dystrophy often benefit from orphan drug designations and expedited review pathways (e.g., Fast Track, Accelerated Approval). However, these pathways do not reduce the rigor of CMC requirements.

The FDA has issued guidance documents relevant to oligonucleotide therapies, and ongoing dialogue between manufacturers and regulatory agencies is crucial to navigate the specific challenges of ASO manufacturing and ensure timely approval and market access. Sarepta’s experience with prior ASO approvals for DMD provides them with established relationships and a known track record with the FDA, which is advantageous for Casimersen.

How Does Casimersen's Manufacturing Strategy Compare to Other ASO Therapies?

Casimersen (KAHUNA) is part of Sarepta Therapeutics' portfolio of RNA-targeted therapies for Duchenne muscular dystrophy (DMD). Its manufacturing strategy, like other ASOs in Sarepta's pipeline, is characterized by a focus on specialized oligonucleotide synthesis and a hybrid approach leveraging both internal capabilities and external CDMO partnerships.

Comparison Points:

• Technology Platform: Casimersen, like eteplirsen and golodirsen, is a phosphorodiamidate morpholino oligonucleotide (PMO). This differs from other ASOs that may be based on different chemistries like phosphorothioates (PS) or 2'-O-methoxyethyl (MOE) modifications. PMOs have specific manufacturing considerations, particularly regarding their unique backbone structure and synthesis.
• API Synthesis:
  • Internal Capabilities: Sarepta has invested in its own manufacturing facilities, including significant capabilities for the synthesis of PMO APIs. This provides greater control over the early stages of production and allows for proprietary process optimization.
  • External CDMOs: For increased capacity, redundancy, or specialized steps, Sarepta likely utilizes experienced oligonucleotide CDMOs. Companies like Nitto Avecia are known to be significant players in ASO API manufacturing, and it is plausible they are involved in Sarepta's supply chain for one or more of its ASO drugs.
• Scale of Production: As Casimersen's indication is for a specific subset of DMD patients (those amenable to exon 45 skipping), the initial commercial scale required is manageable for a focused CDMO or Sarepta’s internal facilities. However, the demand could increase with broader access or potential label expansions, necessitating robust scalability plans.
• Formulation and Fill-Finish: The final drug product formulation and sterile fill-finish operations (converting the API into the injectable solution) are critical. These are typically handled by specialized CDMOs with sterile manufacturing capabilities, or potentially by Sarepta’s internal facilities if equipped.
• Cost of Goods (COGS): The cost of ASO manufacturing remains a significant challenge across the industry. Sarepta's strategy likely aims to optimize COGS through process efficiencies in their internal manufacturing and strategic negotiation with CDMO partners. The specialized nature of PMO synthesis and the cost of raw materials contribute to higher COGS compared to many small molecules.
• Regulatory Path: Sarepta has navigated the regulatory pathways for its previous ASO drugs, establishing a precedent with agencies like the FDA. This experience informs the regulatory strategy for Casimersen, ensuring that CMC data and manufacturing controls meet established standards.

Comparison to Other ASO Types:

• Phosphorothioate (PS) ASOs: These are more established in the market. Manufacturing is generally well-understood, but they can have off-target binding issues.
• 2'-O-Methoxyethyl (MOE) ASOs: These offer improved nuclease resistance and binding affinity compared to PS ASOs, but their synthesis also involves specific chemical steps.
• PMOs (Casimersen's class): These have a unique morpholino backbone and are designed to resist enzymatic degradation. Their synthesis requires specialized phosphoramidite chemistry and purification techniques.

Sarepta's established expertise in PMO chemistry and manufacturing provides a solid foundation for Casimersen. Their dual strategy of internal investment and external partnerships allows for flexibility, risk mitigation, and scalability in response to market demand and potential future growth.

Key Takeaways

• Specialized Manufacturing: Casimersen, as an antisense oligonucleotide (ASO), requires specialized chemical synthesis capabilities, particularly for its phosphorodiamidate morpholino (PMO) structure.
• Key Supplier Landscape: Primary suppliers are oligonucleotide synthesis CDMOs and companies with expertise in nucleic acid API manufacturing. Prominent players in the broader oligonucleotide synthesis market include Agilent Technologies, LGC Biosearch Technologies, Nitto Avecia, Bachem, and WuXi AppTec.
• Sarepta's Hybrid Strategy: Sarepta Therapeutics employs a hybrid manufacturing strategy, combining internal synthesis and manufacturing capabilities with strategic partnerships with specialized CDMOs to ensure capacity, redundancy, and scalability.
• Manufacturing Challenges: Key challenges include the complexity of multi-step chemical synthesis, difficulties in large-scale production, stringent purity requirements, high raw material costs, and extensive process validation demands.
• Regulatory Rigor: ASO drug manufacturing is subject to strict regulatory oversight, focusing on GMP compliance, comprehensive CMC data, impurity control, and process validation by agencies like the FDA and EMA.
• PMO Specifics: Casimersen's PMO chemistry presents unique manufacturing considerations distinct from other ASO backbone chemistries.

Frequently Asked Questions

1. What specific chemical modifications are present in Casimersen that differentiate its synthesis requirements from other ASO drugs? Casimersen is a phosphorodiamidate morpholino oligonucleotide (PMO). This backbone structure differs from more common phosphorothioate (PS) or 2'-O-methoxyethyl (MOE) chemistries, necessitating the use of specific morpholino-based phosphoramidite building blocks and a unique synthesis pathway to assemble the oligo chain.

2. Does Sarepta Therapeutics manufacture the Casimersen API entirely in-house, or do they rely on external contract manufacturing organizations (CMOs/CDMOs)? Sarepta Therapeutics utilizes a hybrid manufacturing strategy. They have invested in internal manufacturing capabilities for their ASO pipeline, including PMO API synthesis. However, they also partner with specialized external CDMOs to ensure sufficient capacity, redundancy, and to leverage specific manufacturing expertise.

3. What are the primary analytical techniques used to ensure the purity and quality of Casimersen API? Ensuring the purity of Casimersen API involves a suite of advanced analytical techniques. These typically include High-Performance Liquid Chromatography (HPLC) for assessing purity and quantifying related substances, Mass Spectrometry (MS) for molecular weight confirmation and impurity identification, and Nuclear Magnetic Resonance (NMR) spectroscopy for structural elucidation. Capillary gel electrophoresis (CGE) may also be employed for purity analysis.

4. What is the typical scale of oligonucleotide synthesis required for a drug like Casimersen, and how does this impact supplier selection? The scale of oligonucleotide synthesis for Casimersen depends on the patient population size for its indicated use (DMD patients amenable to exon 45 skipping). While initial commercial volumes might be in the range of kilograms, suppliers must demonstrate the capability to scale up to multi-kilogram or even metric ton production to meet potential demand fluctuations or market growth. This requires CDMOs with robust large-scale synthesis platforms and purification systems.

5. How do the regulatory requirements for manufacturing oligonucleotide therapies like Casimersen differ from those for traditional small-molecule drugs? While both require adherence to cGMP, oligonucleotide manufacturing faces unique regulatory challenges related to the complex chemical synthesis and the potential for a wider range of process-related impurities (e.g., truncated sequences, incompletely modified nucleotides). Regulatory scrutiny focuses heavily on the robust characterization of the API, detailed impurity profiling, extensive process validation, and demonstrating control over a highly complex multi-step chemical process.

Citations

[1] Sarepta Therapeutics. (n.d.). Pipeline: Duchenne Muscular Dystrophy. Retrieved from https://www.sarepta.com/pipeline/dmd [2] Nitto Avecia. (n.d.). Oligonucleotide Manufacturing. Retrieved from https://www.nitto.com/us/en/products/other/avec/ [3] Bachem. (n.d.). Oligonucleotides. Retrieved from https://bachem.com/markets-and-technologies/oligonucleotides/ [4] WuXi AppTec. (n.d.). Oligonucleotide Therapeutics Manufacturing. Retrieved from https://www.wuxiapptec.com/services/drug-manufacturing/oligonucleotide-therapeutics-manufacturing [5] U.S. Food and Drug Administration. (n.d.). Guidance for Industry. (Specific guidance documents related to oligonucleotides and CMC are available on the FDA website, though a single overarching document is rare; relevant sections are incorporated into general CMC guidelines). [6] European Medicines Agency. (n.d.). Quality of Medicines and Healthier Substances. (Similar to FDA, EMA provides guidance on CMC requirements applicable to all medicines, including advanced therapies).